Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan to reduce grade ≥2 radiation pneumonitis after thoracic radiotherapy
ChiCTR2200062762Phase 4Not yet recruiting
- Sponsor
- Central Hospital Affiliated to Shandong First Medical University
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of valsartan in bronchial carcinoma and radiation pneumonitis (RP), sponsored by Central Hospital Affiliated to Shandong First Medical University. Primary endpoint: Incidence of grade 2 or higher radiation pneumonitis within 3 months after radiotherapy. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
valsartan
03
Conditions
bronchial carcinomaradiation pneumonitis (RP)
Beyond the preview
Go deeper on ChiCTR2200062762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062762.